Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07009860 · ClinicalTrials.gov registry record · Phase 2
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
A Phase 2 study of Alcohol Liver Disease, sponsored by Altimmune.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07009860 is a Phase 2 study of Alcohol Liver Disease that is actively recruiting participants, run by Altimmune. The registered enrollment target is 100 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT07009860, a Phase 2 study of Alcohol Liver Disease, is actively recruiting participants, sponsored by Altimmune.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Pemvidutide
Study Locations (20)
Florida
- Altimmune Clinical Study Site - Bradenton
- Altimmune Clinical Study Site - Doral
- Altimmune Clinical Study Site - Doral
- Altimmune Clinical Study Site - Fort Myers
- Altimmune Clinical Study Site - Miami
- Altimmune Clinical Study Site - Miami
- Altimmune Clinical Study Site - Miami Lakes
- Altimmune Clinical Study Site - Naples
- Altimmune Clinical Study Site - Orlando
- Altimmune Clinical Study Site - Port Orange
Arizona
- Altimmune Clinical Study Site - Peoria
- Altimmune Clinical Study Site - Tucson
- Altimmune Clinical Study Site - Tuscon
California
- Altimmune Clinical Study Site - Fresno
- Altimmune Clinical Study Site - La Jolla
- Altimmune Clinical Study Site - Pasadena
Arkansas
- Altimmune Clinical Study Site - North Little Rock
Colorado
- Altimmune Clinical Study Site - Englewood
Georgia
- Altimmune Clinical Study Site - Atlanta
Indiana
- Altimmune Clinical Study Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07009860
The ClinicalTrials.gov registry entry for NCT07009860 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07009860 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT07009860 about?
NCT07009860 is a clinical study titled "RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
What is the current status of trial NCT07009860?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-06-16. Estimated completion is 2027-08-31.
What conditions does trial NCT07009860 study?
This clinical trial studies the following conditions: Alcohol Liver Disease.
What interventions are being tested in trial NCT07009860?
The interventions under investigation include: Placebo (OTHER), Pemvidutide (DRUG).
Who is sponsoring clinical trial NCT07009860?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07009860 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.